Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
The purpose of the protocol is to evaluate and describe QoL, in the population of Polish
 acromegalic patients treated with Lanreotide Autogel® 120 mg during the 24 months (long term
 observation).
Inclusion Criteria:

 -  Adult patients with acromegaly treated for at least three months and no longer than
 three years with Lanreotide Autogel® 120 mg just before inclusion.

 -  Patients capable of giving their informed consent to participate in the study and who
 agree to participate by signing the informed consent form.

 Exclusion Criteria:

 -  Active participation in any interventional or any other non-interventional acromegaly
 clinical study. (Previous participation in any interventional or any observational /
 post marketing study (PMS) of other somatostatin analogue should not be an exclusion
 criteria).

 -  Any medical or psychological condition, according to investigator judgement, that
 might compromise the ability to give informed consent.